Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 ROA % is 11.78% as of Dec. 2025, which is 34% above its 10-year median of 8.81. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 89.25% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. WuXi XDC Cayman's annualizedNet Income for the quarter that ended in Dec. 2025 was HK$1,623 Mil.
WuXi XDC Cayman's average Total Assets over the quarter that ended in Dec. 2025 was HK$13,779 Mil. Therefore, WuXi XDC Cayman's annualized ROA % for the quarter that ended in Dec. 2025 was 11.78%.
The historical rank and industry rank for WuXi XDC Cayman's ROA % or its related term are showing as below:
HKSE:02268'
s ROA % Range Over the Past 10 Years
Min: 6.11 Med: 8.81 Max: 13.35
Current: 11.6
During the past 6 years, WuXi XDC Cayman's highest ROA % was 13.35%. The lowest was 6.11%. And the median was 8.81%.
HKSE:02268's ROA % is ranked better than 89.25% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.66
vs HKSE:02268: 11.60
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
WuXi XDC Cayman ROA % Related Terms
WuXi XDC Cayman ROA % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's ROA % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
WuXi XDC Cayman (HKSE:02268) has a ROA % of 11.78% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on WuXi XDC Cayman and its competitors. This is 34% above median its historical median of 8.81. Over the past decade, WuXi XDC Cayman's ROA % has ranged from 6.11 to 13.35. According to the industry distribution chart, WuXi XDC Cayman ranks #23 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 10.7%.
Is WuXi XDC Cayman's ROA % too high?
WuXi XDC Cayman's current ROA % of 11.78% is 34% above median its 10-year median of 8.81. Over the past 10 years, this metric has ranged from a low of 6.11 to a high of 13.35. Based on the distribution chart, WuXi XDC Cayman ranks #23 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #23 out of 214 companies for ROA %. This places WuXi XDC Cayman in the top 11% of its industry — outperforming the majority of peers. Historically, WuXi XDC Cayman's own ROA % has ranged from 6.11 to 13.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current ROA % is 11.78%, which is 34% above median its own 10-year median of 8.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current ROA % of 11.78%. The current ROA % is 11.78%, which is 34% above median its 10-year median of 8.81. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current ROA % is 11.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
